drugset / Trial / NCT01866423
Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Phase 2
Terminated
4 enrolled
University of Southern California
Millennium Pharmaceuticals, Inc. · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well orteronel works in treating patients with metastatic hormone-resistant prostate cancer. Orteronel may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2013-10-25
- Primary completion
- 2015-07-23
- Completion
- 2016-07-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Orteronel | Small molecule | 300 mg | Oral |